Cytodyn is a company that develops treatments and therapies for people with infections and immune deficiency viruses. The company was founded in 2002 in Lake Oswego, Oregon, United States.
The company is primarily interested in creating products and solutions to impact HIV and AIDS issues. The company's main pursuit is to develop a monoclonal antibody receptor antagonist that help prevent HIV, GVHD, NASH, and cancer from metastasizing on and using the CCR5 receptors as a gateway to healthy cells. The antibody is known as Leronlimab.
The company has began developing solutions in response to the outbreak of COVID-19. The company has began protocol for a Phase 2 clinical trial for the treatment of patients with the coronavirus through the use of Leronlimab. The company believes that the virus can progress into pneumonia and eventually death due to acute respiratory distress syndrome.
The treatments with Leronlimab that Cytodyn has developed have been approved as a therapy for patients who experience respiratory issues as a result of the coronavirus disease. Leronlimab has a resonse against pathogen in the areas of inflammation and the migration of macrophages and the release of cytokines (what causes the damage in the lungs of certain patients). The company believes that the use of Leronlimab will reduce the morbdity and mortality of severe cases of COVID-19. Cytodyn has partnered with IncellDx to develop a suite of diagnostics to monitor the effects of the monoclonal antibody receptors.
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Coronavirus Patients with Leronlimab (PRO 140)
March 9, 2020
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)
March 8, 2020